EFFECTIVENESS OF HORMONAL TREATMENT IN PATIENTS WITH COMBINED ENDOMETRIAL PATHOLOGY AND BENIGN FORMATIONS OF MAMMARY GLANDS

Abstract

Issues related to the treatment of HPE are still very relevant, which is due to the high frequency of relapses of this disease. Today, in the arsenal of modern medicine, there are various approaches to the treatment of HPE. However, the development of benign neoplasms of the mammary glands against the background of HPE limits the possibilities of conservative treatment. Hormonal therapy remains one of the most common methods of treating HPE. The purpose of the study: to optimize the treatment of patients with various types of hyperplastic processes of the endometrium in combination with benign diseases of the mammary glands. Materials and methods. A prospective study of 90 women aged 18 to 47 was conducted. The main group consisted of patients who were diagnosed with HPE and benign diseases of the mammary glands. The comparison group included patients who were diagnosed with HPE without accompanying pathology of the mammary glands. For the treatment of endometrial hyperplasia without atypia, medroxyprogesterone was used, for the treatment of atypical endometrial hyperplasia, medroxyprogesterone was used in combination with a gonadotropin-releasing hormone analog. For the treatment of patients with combined pathology, the commercial drug Danazol or medroxyprogesterone in combination with Koberlin was used. The results. The implementation of various treatment regimens for patients with HPE and benign breast neoplasms showed that the more effective treatment regimen was the one involving the use of Danazol. In this group of patients, the levels of estradiol and progesterone in the blood plasma normalized already after six months of using the drug. Conclusion. The study of the levels of estrogens, progestins and gonadotropic hormones showed that in the patients of the comparison group, the best treatment scheme is the combined use of medroxyprogesterone and gonadotropin-releasing hormone analogues compared to the monouse of only medroxyprogesterone. In patients with the combined pathology of HPE and mastopathy, the best treatment scheme is the use of Danazol.